CeriBell (NASDAQ:CBLL) CEO Sells $717,600.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 39,000 shares of the company’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $18.40, for a total transaction of $717,600.00. Following the completion of the sale, the chief executive officer owned 850,347 shares in the company, valued at $15,646,384.80. This represents a 4.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xingjuan Chao also recently made the following trade(s):

• On Tuesday, March 3rd, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $17.45, for a total transaction of $680,550.00.
• On Monday, February 23rd, Xingjuan Chao sold 2,084 shares of CeriBell stock. The stock was sold at an average price of $19.79, for a total transaction of $41,242.36.

CeriBell Stock Up 4.3%

Shares of CBLL traded up $0.78 on Wednesday, reaching $18.65. The company’s stock had a trading volume of 106,877 shares, compared to its average volume of 326,328. The company has a current ratio of 9.73, a quick ratio of 9.35 and a debt-to-equity ratio of 0.13. CeriBell, Inc. has a twelve month low of $10.01 and a twelve month high of $24.33. The stock has a market capitalization of $701.85 million, a PE ratio of -12.75 and a beta of 0.94. The firm has a fifty day moving average of $19.15 and a 200-day moving average of $17.57.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.07. The company had revenue of $24.78 million for the quarter, compared to analyst estimates of $23.95 million. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. Equities analysts predict that CeriBell, Inc. will post -2.46 EPS for the current year.

Wall Street Analysts Forecast Growth

CBLL has been the subject of a number of research reports. Canaccord Genuity Group increased their target price on shares of CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of CeriBell in a research report on Monday. BTIG Research reissued a “buy” rating and set a $30.00 target price on shares of CeriBell in a research report on Wednesday, January 28th. Finally, TD Cowen reissued a “buy” rating on shares of CeriBell in a research report on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $23.20.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Squarepoint Ops LLC bought a new position in shares of CeriBell in the second quarter worth $1,054,000. Emerald Mutual Fund Advisers Trust increased its holdings in shares of CeriBell by 58.2% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 155,360 shares of the company’s stock worth $1,785,000 after purchasing an additional 57,175 shares during the period. CenterBook Partners LP raised its position in shares of CeriBell by 448.0% during the 3rd quarter. CenterBook Partners LP now owns 476,554 shares of the company’s stock valued at $5,476,000 after buying an additional 389,584 shares in the last quarter. Peregrine Capital Management LLC raised its position in shares of CeriBell by 7.7% during the 3rd quarter. Peregrine Capital Management LLC now owns 367,945 shares of the company’s stock valued at $4,228,000 after buying an additional 26,286 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in shares of CeriBell by 8.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 411,180 shares of the company’s stock valued at $4,724,000 after buying an additional 31,177 shares in the last quarter.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.